NH Investment & Securities Co., Ltd. (005945.KS)
| Previous close | 10,780.00 |
| Open | 10,750.00 |
| Bid | 10,790.00 x 0 |
| Ask | 10,800.00 x 0 |
| Day's range | 10,700.00 - 10,840.00 |
| 52-week range | 8,910.00 - 12,250.00 |
| Volume | |
| Avg. volume | 101,599 |
| Market cap | 4.056T |
| Beta (5Y monthly) | 0.61 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 850.00 (7.88%) |
| Ex-dividend date | 28 Mar 2024 |
| 1y target est | N/A |
PR NewswireUNLIMEAT Pulled Pork Wrap Now Available at All Starbucks Stores in HK
UNLIMEAT announced on the 16th the launch of its Pulled Pork Wrap at Starbucks stores throughout Hong Kong. The UNLIMEAT Pulled Pork Wrap is a fully plant-based product containing UNLIMEAT's pulled pork, along with refreshing carrot, vibrant red cabbage, and crisp lettuce, all wrapped together for a satisfying and guilt-free meal.
PR NewswireImmunoForge Doses First Patient in Phase 2 Clinical Trial of Froniglutide for Dermatomyositis/Polymyositis
ImmunoForge today announced that it has dosed the first patient in its Phase 2 clinical trial to evaluate the efficacy, safety, and pharmacokinetic properties of Froniglutide in patients with dermatomyositis/polymyositis.
PR NewswireImmunoForge Expands Drug Development Licensing Agreement with Duke University
ImmunoForge has announced on the 18th that it has expanded its license rights with Duke University to enhance joint research and drug development opportunities in relation to the elastin-like polypeptide (ELP) platform technology. Through this agreement, ImmunoForge expects to accelerate the development of new drugs based on the ELP technology that was originally developed by Professor Ashutosh Chilkoti at Duke University. Dr. Jim Ballance, Chief Technology Officer (CTO) of ImmunoForge, has pion
